CapeBio Technologies (Pty) Ltd (CapeBio) is a pioneer in genome editing and genome engineering in Africa through its supply of novel proteins and enzymes that are derived from indigenous microbial diversities, namely The Cape Floral Kingdom. This area, also known as the Cape Fynbos biome, is one of the world’s biosphere hotspots with a diverse and high plant biodiversity per unit area. The high plant biodiversity directly translates into high microbial diversity, and has resulted in novel genes for making a wide range of proteins and enzymes used in various industries. The current portfolio includes molecular biology enzymes used by researchers to cut, join and make many copies of DNA molecules in a laboratory setting. In order to preserve South Africa’s indigenous resources for the benefit of future generations and the well-being of the country, CapeBio partners with biodiversity conservation organisations.
CapeBio was formally launched as a private company in 2018, after successfully executing a research and development (R&D) project funded by the Council of Scientific and Industrial Research (CSIR) and the Department of Science and Innovation (DSI). Through the support of these partners they established both the R&D and the end-user beta-testing campaign between 2015 and 2018. The flagship products were given for testing to more than 500 researchers across South Africa, Namibia, Botswana, Kenya and Nigeria, and they received a nearly 100% customer feedback and satisfaction rate.
Their aim is “to shape the African continent for the future by using our innovative bio-discovery research to unlock the power of ancient genomic data”.
Download product brochure: Capebio Product Brochure